Stock Ratings / Health Care / MDCX / options

NRSN (38) DRMA (43) ENLV (35) XTLB (47) ⌘ Pro Terminal →

Medicus Pharma Ltd. (MDCX) Options Positioning, Max Pain & Unusual Sweeps

Q: What is MDCX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for MDCX.

$2.15 -13.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Medicus Pharma Ltd. (MDCX) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $4.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MDCX)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (MDCX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for MDCX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MDCX)

✓Walkthrough of MDCX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MDCX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.81%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.17H $2.18L $1.82C $2.15VOL 86.6K

RES: $7.40SUP: $1.33SMA50: $7.27SMA200: $22.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MDCX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MDCX Butterfly Map → + Track MDCX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MDCX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MDCX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MDCX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDCX)

Health Care Rank #832 of 1016 ⚔️ NRSN vs MDCX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MDCX vs. NRSN, DRMA, ENLV, XTLB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Medicus Pharma Ltd. (MDCX) ranks #832 by composite RQD confidence (35/100, grade D-) and #959 by equity capitalization ($4.1M). Within this direct 5-issuer industry benchmark cohort, MDCX leads on earnings valuation at N/A trailing P/E, while ENLV leads on capital efficiency and profitability with -0.6% ROIC and — gross margin. XTLB currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MDCX at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MDCX ACTIVE Medicus Pharma Ltd.	D-	35/100	—	—	-35.0%	-13.31%	$4.1M	Benchmark Subject
NRSN NeuroSense Therapeutics Ltd.	D-	38/100	—	—	-35.0%	-9.75%	$4.0M	/nrsn-vs-mdcx →
DRMA Dermata Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.84%	$4.2M	/drma-vs-mdcx →
ENLV Enlivex Ltd.	D-	35/100	—	—	-0.6%	-2.68%	$3.9M	/enlv-vs-mdcx →
XTLB XTL Biopharmaceuticals Ltd.	D	47/100	—	—	—	-12.44%	$4.3M	/xtlb-vs-mdcx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001997296

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medicus Pharma Ltd. (MDCX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$47.3M, operating cash flow of -$22.8M, and free cash flow of -$22.8M (-122.3% YoY). On the balance sheet, MDCX closed FY2025 with $10.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$47.3M	-$22.8M	-$22.8M	$10.1M	—
FY2024 (FY)	2024-12-31	$0	-$11.2M	-$10.2M	-$10.2M	$5.6M	—
FY2023 (FY)	2023-12-31	$0	-$5.3M	-$4.2M	-$4.2M	—	—

3. MDCX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MDCX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Medicus Pharma Ltd. (NASDAQ: MDCX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.15 (-13.31% 1D, market cap $4.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MDCX ranks #832 in composite RQD confidence.

How does MDCX compare to NRSN and DRMA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MDCX carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NRSN (NeuroSense Therapeutics Ltd.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M) and DRMA (Dermata Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, MDCX leads on earnings multiple (N/A) while ENLV leads on capital efficiency (-0.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MDCX?

Per MDCX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001997296), Medicus Pharma Ltd. generated $0 in revenue, -$47.3M in net income, and -$22.8M in free cash flow against $10.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MDCX trading relative to its 50-day, 200-day, and 52-week technical levels?

MDCX last traded at $2.15 (-13.31% on volume of 123,516 shares), positioning the stock -70.43% below its 50-day simple moving average ($7.27) and -90.59% below its 200-day simple moving average ($22.85). Across its 52-week range of $1.82 to $127.50, MDCX sits at the 0.3% percentile with a 14-day RSI of 16.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.88 to $2.42).

MDCX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is MDCX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for MDCX.

Direct Sub-Reports: MDCX RQD Cockpit MDCX 12M Forecast MDCX Earnings & Move MDCX Dividends & DRIP MDCX Insiders & 13F MDCX Whale Options MDCX Profit Sankey MDCX News & Why